Edition:
United States

Diplomat Pharmacy Inc (DPLO.N)

DPLO.N on New York Stock Exchange

17.61USD
23 May 2017
Change (% chg)

$0.19 (+1.09%)
Prev Close
$17.42
Open
$17.51
Day's High
$17.70
Day's Low
$17.29
Volume
128,517
Avg. Vol
233,900
52-wk High
$38.91
52-wk Low
$12.25

DPLO.N

Chart for DPLO.N

About

Diplomat Pharmacy, Inc. (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company's primary focus is on medication management programs... (more)

Overall

Beta: --
Market Cap(Mil.): $1,183.35
Shares Outstanding(Mil.): 67.20
Dividend: --
Yield (%): --

Financials

  DPLO.N Industry Sector
P/E (TTM): 69.65 42.06 40.94
EPS (TTM): 0.25 -- --
ROI: 2.00 4.52 53.11
ROE: 2.95 7.10 60.79

BRIEF-Diplomat Pharmacy Q1 revenue $1.079 billion

* Q1 earnings per share view $0.15 -- Thomson Reuters I/B/E/S

May 08 2017

BRIEF-Diplomat acquires WRB Communications

* Diplomat Pharmacy Inc - under terms of agreement, diplomat is paying WRB $24.5 million cash and $4.5 million of diplomat common stock

May 08 2017

BRIEF-Diplomat Pharmacy on March 31,co, units, Celgene entered into pharmacy distribution, services agreement to be effective July 1, 2017

* Diplomat Pharmacy Inc - on March 31,co, units, Celgene Corp entered into a pharmacy distribution and services agreement to be effective July 1, 2017

Apr 13 2017

BRIEF-Diplomat appoints Atul Kavthekar as new CFO

* Diplomat Pharmacy Inc - Appointed Atul Kavthekar as chief financial officer and treasurer, effective May 1, 2017

Apr 11 2017

BRIEF-Regina Benjamin appointed to Diplomat's board of directors

* Dr. Regina Benjamin appointed to Diplomat's board of directors

Apr 06 2017

BRIEF-Diplomat Pharmacy to dispense Kisqali as first-line treatment for postmenopausal women with breast cancer

* Says will dispense Kisqali as a first-line treatment for postmenopausal women with a serious form of breast cancer Source text for Eikon: Further company coverage:

Mar 16 2017

BRIEF-Diplomat Pharmacy to dispense xermelo for patients with carcinoid syndrome diarrhea

* Diplomat Pharmacy Inc says to dispense xermelo for patients with carcinoid syndrome diarrhea Source text for Eikon: Further company coverage:

Mar 06 2017

BRIEF-Diplomat dispensing Revlimid for multiple myeloma maintenance therapy following autologous hematopoietic stem cell transplant (auto-HSCT)

* Diplomat dispensing Revlimid for multiple myeloma maintenance therapy following autologous hematopoietic stem cell transplant (auto-HSCT) Source text for Eikon: Further company coverage:

Mar 02 2017

BRIEF-Diplomat Pharmacy Inc files for non timely 10-K

* Diplomat Pharmacy Inc files for non timely 10-K Source text: (http://bit.ly/2lV9nDo) Further company coverage:

Mar 01 2017

BRIEF-Diplomat provides 2016 financial guidance update

* Now expects 2016 revenue and adjusted EBITDA will be at or near low end of previously announced ranges

Jan 09 2017

More From Around the Web

Earnings vs. Estimates